# Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870

> **NCT02586246** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 86 (actual)

## Conditions studied

- Active Rheumatoid Arthritis

## Interventions

- **DRUG:** CDP870

## Key facts

- **NCT ID:** NCT02586246
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2015-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586246, "Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02586246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*